Anticancer therapeutic strategies based on CDK inhibitors

Luca Esposito, Paola Indovina, Flora Magnotti, Daniele Conti, Antonio Giordano

Research output: Contribution to journalArticle

Abstract

Normal cell cycle progression is controlled by the sequential action of cyclin-dependent kinases (CDKs), the activity of which depends on their binding to regulatory partners (cyclins). Deregulation of cell cycle is one of the first steps that transform normal cells into tumor cells. Indeed, most cancer cells bear mutations in members of the pathways that control the CDK activity. For this reason, this kinase family is a crucial target for the development of new drugs for cancer therapy. Recently, both ATP-competitive CDK inhibitors and the last generation of non-ATP-competitive inhibitors are emerging as promising agents for targeted therapies. Many clinical trials are in progress, using CDK inhibitors both as single agents and in combination with traditional cytotoxic agents. In this review, we will discuss new therapeutic strategies based on the use of CDK inhibitors in cancer.

Original languageEnglish
Pages (from-to)5327-5332
Number of pages6
JournalCurrent Pharmaceutical Design
Volume19
Issue number30
DOIs
Publication statusPublished - 2013

Fingerprint

Cyclin-Dependent Kinases
Neoplasms
Cell Cycle
Therapeutics
Cyclins
Cytotoxins
Phosphotransferases
Adenosine Triphosphate
Clinical Trials
Drug Therapy
Mutation

Keywords

  • Anticancer therapeutics
  • Cancer
  • CDK inhibitors
  • CDKs
  • Cell cycle

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Esposito, L., Indovina, P., Magnotti, F., Conti, D., & Giordano, A. (2013). Anticancer therapeutic strategies based on CDK inhibitors. Current Pharmaceutical Design, 19(30), 5327-5332. https://doi.org/10.2174/13816128113199990377

Anticancer therapeutic strategies based on CDK inhibitors. / Esposito, Luca; Indovina, Paola; Magnotti, Flora; Conti, Daniele; Giordano, Antonio.

In: Current Pharmaceutical Design, Vol. 19, No. 30, 2013, p. 5327-5332.

Research output: Contribution to journalArticle

Esposito, L, Indovina, P, Magnotti, F, Conti, D & Giordano, A 2013, 'Anticancer therapeutic strategies based on CDK inhibitors', Current Pharmaceutical Design, vol. 19, no. 30, pp. 5327-5332. https://doi.org/10.2174/13816128113199990377
Esposito, Luca ; Indovina, Paola ; Magnotti, Flora ; Conti, Daniele ; Giordano, Antonio. / Anticancer therapeutic strategies based on CDK inhibitors. In: Current Pharmaceutical Design. 2013 ; Vol. 19, No. 30. pp. 5327-5332.
@article{55fc3640d50447978c0394ca2329161c,
title = "Anticancer therapeutic strategies based on CDK inhibitors",
abstract = "Normal cell cycle progression is controlled by the sequential action of cyclin-dependent kinases (CDKs), the activity of which depends on their binding to regulatory partners (cyclins). Deregulation of cell cycle is one of the first steps that transform normal cells into tumor cells. Indeed, most cancer cells bear mutations in members of the pathways that control the CDK activity. For this reason, this kinase family is a crucial target for the development of new drugs for cancer therapy. Recently, both ATP-competitive CDK inhibitors and the last generation of non-ATP-competitive inhibitors are emerging as promising agents for targeted therapies. Many clinical trials are in progress, using CDK inhibitors both as single agents and in combination with traditional cytotoxic agents. In this review, we will discuss new therapeutic strategies based on the use of CDK inhibitors in cancer.",
keywords = "Anticancer therapeutics, Cancer, CDK inhibitors, CDKs, Cell cycle",
author = "Luca Esposito and Paola Indovina and Flora Magnotti and Daniele Conti and Antonio Giordano",
year = "2013",
doi = "10.2174/13816128113199990377",
language = "English",
volume = "19",
pages = "5327--5332",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "30",

}

TY - JOUR

T1 - Anticancer therapeutic strategies based on CDK inhibitors

AU - Esposito, Luca

AU - Indovina, Paola

AU - Magnotti, Flora

AU - Conti, Daniele

AU - Giordano, Antonio

PY - 2013

Y1 - 2013

N2 - Normal cell cycle progression is controlled by the sequential action of cyclin-dependent kinases (CDKs), the activity of which depends on their binding to regulatory partners (cyclins). Deregulation of cell cycle is one of the first steps that transform normal cells into tumor cells. Indeed, most cancer cells bear mutations in members of the pathways that control the CDK activity. For this reason, this kinase family is a crucial target for the development of new drugs for cancer therapy. Recently, both ATP-competitive CDK inhibitors and the last generation of non-ATP-competitive inhibitors are emerging as promising agents for targeted therapies. Many clinical trials are in progress, using CDK inhibitors both as single agents and in combination with traditional cytotoxic agents. In this review, we will discuss new therapeutic strategies based on the use of CDK inhibitors in cancer.

AB - Normal cell cycle progression is controlled by the sequential action of cyclin-dependent kinases (CDKs), the activity of which depends on their binding to regulatory partners (cyclins). Deregulation of cell cycle is one of the first steps that transform normal cells into tumor cells. Indeed, most cancer cells bear mutations in members of the pathways that control the CDK activity. For this reason, this kinase family is a crucial target for the development of new drugs for cancer therapy. Recently, both ATP-competitive CDK inhibitors and the last generation of non-ATP-competitive inhibitors are emerging as promising agents for targeted therapies. Many clinical trials are in progress, using CDK inhibitors both as single agents and in combination with traditional cytotoxic agents. In this review, we will discuss new therapeutic strategies based on the use of CDK inhibitors in cancer.

KW - Anticancer therapeutics

KW - Cancer

KW - CDK inhibitors

KW - CDKs

KW - Cell cycle

UR - http://www.scopus.com/inward/record.url?scp=84881361773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881361773&partnerID=8YFLogxK

U2 - 10.2174/13816128113199990377

DO - 10.2174/13816128113199990377

M3 - Article

C2 - 23394082

AN - SCOPUS:84881361773

VL - 19

SP - 5327

EP - 5332

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 30

ER -